BioSpace News Archive

A novel study published in AACC’s Clinical Chemistry journal shows that a machine learning-based test detects emerging synthetic cannabinoids with greater ease than standard methods.

OSF Ventures joins six other investors in a Series A, $12.5 million funding round for a wireless, wearable EEG (brain wave monitor) to detect seizures, even those that are non-convulsive with no obvious signs.

Since decades, vaccines, also referred as immunization, has been saving lives of people worldwide, especially among children and older individuals.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced fourth quarter and full year 2021 financial results and provided an operational update.

CSL Plasma, the plasma collection business of global biotherapeutics leader CSL Behring, today welcomes the regulatory clearance of the Rika Plasma Donation System developed by Terumo Blood and Cell Technologies, a medical technology company based in Lakewood, Colorado.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its fourth quarter and full year 2021 financial results on Thursday, March 17, 2022.

Global Blood Therapeutics, Inc. announced that on March 1, 2022, the compensation committee of GBT’s board of directors granted 19 new employees restricted stock units for an aggregate of 42,380 shares of the company’s common stock.

Eargo, Inc. announced the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC on March 4, 2022 indicating that, because the Company has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, the Company does not comply with Nasdaq Listing Rule 5250 for continued listing.

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the year ended December 31, 2021, announced plans to conduct interim analyses of its OraGrowtH210 and OraGrowtH212 Trials, and provided an update on clinical activities and financial guidance for 2022.

Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that its Chief Executive Officer, Dr. Roger Crystal, will participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference taking place virtually March 15 - March 17.